Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 1;43(5):e655-e660.
doi: 10.1097/MPH.0000000000001972.

Complications of Central Venous Access Devices in Patients With Sickle Cell Disease and Thalassemia Major

Javier Ordóñez  1 , Agustín Del Cañizo  1 , Cristina Beléndez  2 , Marina García-Morín  2 , Laura Pérez-Egido  1 , María Fanjul  1 , María A García-Casillas  1 , Julio Cerdá  1 , David Peláez  1 , Eduardo Bardón  2 , Juan C de Agustín  1 , Elena Cela  2
Affiliations

Complications of Central Venous Access Devices in Patients With Sickle Cell Disease and Thalassemia Major

Javier Ordóñez et al. J Pediatr Hematol Oncol. .

Abstract

Pediatric patients with sickle cell disease and thalassemia major present clinical characteristics that could lead to a higher incidence of central venous access devices-associated complications (CVAD-C). With the objective of analyzing the safety of the use of CVAD in these patients, a retrospective review including all pediatric patients with these pathologies who required the implantation of a CVAD between 2004 and 2019 was performed. In all, 54 patients with 100 CVAD (65 totally implantable venous access port with subcutaneous reservoir, 35 single-lumen or double-lumen partially tunneled catheter) were included. During 60,410 days at risk of suffering a CVAD-C, 55 complications (complication rate [CR]/1000 catheter-days at risk=0.91) were reported in 46 CVAD: 19 mechanicals (CR=0.32), 32 infectious (CR=0.53), and 4 thrombotic complications (CR=0.066). Incidence of mechanical and infectious complications was significantly higher in double-lumen partially tunneled catheter than in totally implantable venous access port with subcutaneous reservoir (P<0.001). Lower age at insertion was related with a higher incidence of any complication (odds ratio=0.88/y, P=0.02). Patients who required a stem cell transplantation (31 patients and 65 CVAD) had no significant higher incidences of CVAD-C. In conclusion, our study supports the safety of using CVAD in these patients, with a low incidence of infectious, thrombotic, and mechanical complications.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033–1048.
    1. Cela De Julián E, Dulín Íñiguez E, Guerrero Soler M, et al. Evaluación en el tercer año de implantación del cribado neonatal universal de anemia falciforme en la Comunidad de Madrid [Evaluation of systematic neonatal screening for sickle cell diseases in Madrid three years after its introduction]. An Pediatr. 2007;66:382–386.
    1. Carraro F, Cicalese MP, Cesaro S, et al. Guidelines for the use of long-term central venous catheter in children with hemato-oncological disorders. on behalf of supportive therapy working group of Italian Association of Pediatric Hematology and Oncology (AIEOP). Ann Hematol. 2013;92:1405–1412.
    1. Rincón-López EM, Navarro Gómez ML, Hernández-Sampelayo Matos T, et al. Low-risk factors for severe bacterial infection and acute chest syndrome in children with sickle cell disease. Pediatr Blood Cancer. 2019;66:e27667.
    1. Booth C, Inusa B, Obaro SK. Infection in sickle cell disease: a review. Int J Infect Dis. 2010;14:2–12.